RE:RE:RE:RE:RE:It's on Twitter... ASCO ResultsFurthermore ONCY's Bracelet-1 Phase 2 results were obtained from heavily pre-treated estrogen postive/HER2 negative metastatic breast cancer patients who failed on estrogen and CDK 4/6 therapies. Consequently the 6 month PFS of 86% represents a Confidence Index of 95% that single agent pelareorep was between 54% and 96% better that the control group of paclitaxel alone.
Initiating treatment on early breast cancer patients would produce even better results.